Pedro Jorge Gomes Teodósio Castelo Branco
Professor associado com agregação
Faculdade de Medicina e Ciências Biomédicas
Subsistema
Docentes Universitário
Unidade ID externa
Programa Champalimaud de Investigação (CR)
Regime
Exclusividade
Vínculo
CT em Funções Públicas por tempo indeterminado
Atividades
Atividades
2019 - 2021. Membro de comissão. Integrated Masters in Medicine Appeal Committee. Presidente / Vice-presidente. Universidade do Algarve.
2020 - Presente. Membro de comissão. National Clinical Academic Centres Council. Membro.
2020. Júri de grau académico. Melanoma in zebrafish disregards telomere maintenance mechanisms.. Arguente principal. Joana Nabais (Doutoramento). Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar.
2020 - Presente. Membro de comissão. Doctoral Program in Clinical Research. Membro. Universidade do Algarve.
2020 - Presente. Membro de comissão. Advisory Committee SciELO . Membro.
2019 - 2020. Membro de comissão. Coordinating Section of the Academic Senate. Membro. Universidade do Algarve.
2019 - Presente. Orientação. Epidemiologia molecular de biomarcadores de cancro esófago-gástrico. Coorientador.
2015 - 2019. Orientação. The diagnostic, prognostic and therapeutic role of THOR in breast cancer.. Orientador.
2015 - 2019. Orientação. The role of telomere maintenance in urologic maligancies.. Orientador.
2019 - Presente. Orientação. Modulating receptor activation, migration and epigenetics of cancer cells using UV light.. Coorientador.
2018 - 2019. Membro de comissão. Integrated Masters in Medicine Appeal Committee. Membro. Universidade do Algarve.
2019/12. Apresentação oral de trabalho. Marcadores epigenéticos: A nova era da genética molecular. . Jornadas ALTBiotech. Instituto Nacional de Investigação em Agronomia e Veterinária (Santarém, Portugal).
2019/06 - 2019/06. Curso / Disciplina lecionado. How to communicate ideas, projects and results. .
2019/06 - 2019/06. Curso / Disciplina lecionado. Epigenetic TERT regulation in cancer: from bench to bedside.
2019/02. Apresentação oral de trabalho. TERT regulation in cancer: a potential therapeutic target. . Epigenetic Chemical Biology COST CM1406 Scientific Workshop . Universidade do Algarve (Faro).
2019/01. Apresentação oral de trabalho. Epigenética no cancro colorectal. . I Jornadas de cirurgia colorrectal do Algarve .
2018. Apresentação oral de trabalho. Clinical applications of epigenetic biomarkers in cancer diagnosis and prognosis. MEDLAB Europe, 18 Conferences.
2018 - Presente. Orientação. Uncovering differential DNA methylation alterations in subtypes of Acute Myeloid Leukemia.. Orientador.
2018 - Presente. Orientação. Epigenetics hotspots in cancer. Orientador.
2018 - Presente. Membro de comissão. Doctoral Program in Mechanisms of Disease and Regenerative Medicine, University of Algarve/Nova Lisbon University
- Board member. Membro.
- Board member. Membro.
2018/12. Apresentação oral de trabalho. Tumor Heterogeneity – what do we need to be aware of. …1st Portuguese Symposium on Research and Innovation in Urology. CUF Hospitals (Lisboa).
2018/05 - 2018/05. Curso / Disciplina lecionado. Epigenetic TERT regulation in cancer: from bench to bedside. University of New South Wales.
2017 - Presente. Orientação. Epigenetic biomarker development and big data analysis in Colorectal Cancer. Orientador.
2013 - 2017. Orientação. Proliferación cellular y regulacíon de Telomerasa en el cáncer de mama.. Coorientador.
2017/06. Júri de grau académico. Thymic stromal factors promoting T-cell leukemia. Marinella Nobre Ghezzo (Doutoramento).
2017/06. Júri de grau académico. MicroRNA Deregulation in Prostate Cancer. Arguente principal. João António Ramalho Carvalho (Doutoramento). Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar.
2017/06. Júri de grau académico. Biophysical modulation of cell fate through chromatin remodeling.. Arguente principal. Ana Francisca Silva de Lima (Doutoramento). Universidade Nova de Lisboa.
2017/06. Júri de grau académico. The impact f non-coding alterations in glioma: hints from HOTAIR and the TERT promoter. Arguente principal. Ana Xavier Silva Magalhães (Doutoramento). Universidade do Minho Escola de Medicina.
2016 - Presente. Membro de associação. Algarve Biomedical Center. Member of the Executive Committee .
2016. Júri de grau académico. Unravelling the genetics of neuroendocrine tumors. Arguente principal. João Pedro Rico de Oliveira Vinagre (Doutoramento). Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar.
2016. Júri de grau académico. HOXA9 as a key regulator in glioma initiation, aggressiveness and response to therapy.. Arguente principal. Marta Sofia Pojo Sousa (Doutoramento).
2016 - Presente. Membro de comissão. Algarve Biomedical Center
Member of the Executive Committee
. Presidente / Vice-presidente. Algarve Biomedical Center.
Member of the Executive Committee
. Presidente / Vice-presidente. Algarve Biomedical Center.
2016/11 - 2016/11. Curso / Disciplina lecionado. TERT Hypermethylated Oncologic Region - THOR: a new epigenetic cancer biomarker . Oxford Brookes University.
2016/11. Apresentação oral de trabalho. Epigenetics in cancer: From Bench to Clinic. V Simpósio Ciências Biomédicas .
2016/10 - 2016/10. Curso / Disciplina lecionado. Epigenetics in cancer: From Bench to Clinic. . Epigenética Aplicada ao Diagnóstico Laboratorial. Instituto Politécnico de Lisboa Escola Superior de Tecnologia da Saúde de Lisboa.
2016/06. Apresentação oral de trabalho. TERT: factor de prognóstico nos tumores cerebrais pediátricos. 2nd MEEting do MIM. Universidade do Algarve (Faro).
2015 - Presente. Membro de comissão. Department of Biomedical Sciences and Medicine Scientific Council. Membro.
2015/12 - 2015/12. Curso / Disciplina lecionado. A metilação do promotor TERT como factor de prognóstico nos tumores cerebrais pediátricos.
2015/12 - 2015/12. Curso / Disciplina lecionado. TERT Hypermethylated Oncologic Region - THOR: a new epigenetic cancer biomarker.
2015/06. Apresentação oral de trabalho. TERT Hypermethylated Oncologic Region - THOR: a new epigenetic cancer biomarker.. IPATIMUP (Porto).
2015/03. Apresentação oral de trabalho. TERT Hypermethylated Oncologic Region - THOR: a new epigenetic cancer biomarker.. VI Jornadas de Ciencias Biomédicas.
2014 - Presente. Membro de comissão. Genetic Toxicology – Master´s Degree in Oncobiology.. Coordenador. Universidade do Algarve.
2014 - Presente. Membro de comissão. Elective – Medical Degree.. Coordenador. Universidade do Algarve.
2014 - Presente. Membro de comissão. Epigenetics – Biomedical Sciences Degree.. Coordenador. Universidade do Algarve.
2014 - Presente. Curso / Disciplina lecionado. Tumor Progression . Universidade do Algarve.
2014 - Presente. Curso / Disciplina lecionado. Eukaryotic Molecular Genetics - Master´s Degree in Microbial and Molecular Biology. Universidade do Algarve.
2014 - Presente. Curso / Disciplina lecionado. Oncolabs I – Master´s Degree in Oncobiology. Universidade do Algarve.
2014 - Presente. Curso / Disciplina lecionado. Problem Based Learning – Medical Degree..
2014 - Presente. Curso / Disciplina lecionado. Human Genetics – Biomedical Sciences Degree. Universidade do Algarve.
2014 - Presente. Curso / Disciplina lecionado. Congenital Diseases – Biomedical Sciences Degree. Universidade do Algarve.
2014 - Presente. Orientação. Endothelium non-codificant transcriptome in Neurofibromatosis type 1:“instructing cancer".. Coorientador.
2014/11. Apresentação oral de trabalho. TERT Hypermethylated Oncological Region - THOR predicts biochemical relapse amongst prostate cancer patients. 1st ASPIC International meeting.
2013/06. Apresentação oral de trabalho. THOR methylation provides insight into the telomere maintenance landscape of malignant gliomas.
2013/05. Apresentação oral de trabalho. Methylation of a specific region in the hTERT promoter is a cancer signature which correlates with tumor grade and patient survival. .
2013/04. Apresentação oral de trabalho. hTERT promoter methylation: a DNA based epigenetic cancer biomarker. Global Biomarker Conference.
2012/10. Apresentação oral de trabalho. hTERT promoter methylation: An epigenetic cancer biomarker.. CNC. Universidade de Coimbra.
2012/10. Apresentação oral de trabalho. hTERT promoter methylation: A DNA-based cancer biomarker. Cancer Research Center.
2012/10. Apresentação oral de trabalho. From cancer stem cell therapies to the development of a brain tumor biomarker. PhD program. Faculdade de Medicina de Coimbra.
2012/06. Apresentação oral de trabalho. A specific region in the hTERT promoter can predict malignancy and survival in patients with childhood brain tumors.. . 15th International Symposium on Pediatric Neuro-Oncology . ISPNO (Toronto).
2011/04. Apresentação oral de trabalho. Neural tumor initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition. 6th International Meeting of the Portuguese Society for Stem Cells and Cell Therapies.
2010/06. Apresentação oral de trabalho. Selective targeting of neural tumor initiating cells by telomerase inhibition. 14th International Symposium on Pediatric Neuro-Oncology.
2010/05. Apresentação oral de trabalho. Selective targeting of neural tumor initiating cells by telomerase inhibition. 7th Canadian Telomeres and Telomerase Symposium.
2010/04. Apresentação oral de trabalho. Selective Targeting of Pediatric Neural Stem Cells by Telomerase Inhibition. CNC. Universidade de Coimbra.
2010/04. Apresentação oral de trabalho. Telomeres and Telomerase in Aging and Cancer.. Universidade de Aveiro.
2009/01. Apresentação oral de trabalho. Fighting Tumors with virus and telomerase inhibitors. Universidade do Algarve.
2006 - 2008. Tutoria. Biological Sciences . ..
2006 - 2007. Curso / Disciplina lecionado. Teaching fellow in Biological Sciences. Molecular Biology . Harvard University Department of Molecular and Cellular Biology.
2002 - 2003. Curso / Disciplina lecionado. Molecular biology laboratory techniques. University of Oxford Medical Sciences Division.
2003/08. Apresentação oral de trabalho. Polypyrimidine Tract Binding Protein modulates efficiency of polyadenylation. Eukaryotic mRNA processing meeting.
2000/09. Apresentação oral de trabalho. PTB, a multifunctional protein, is a component of the C2 mRNA 3´end formation machinery.. XII Congresso de Bioquímica.
Projetos
Projetos
2011 - 2013. O efeito de terapeuticas usadas no carcinoma da prostata na subpopulação de células estaminais cancerosas prostáticas. Investigador.
2019 - 2024. Epigenetic Marks for Human Sepsis. Investigador. Canadian Institutes of Health Research.
2018 - 2019. Xenografting of bovine ovarian tissue as a model for testing new drugs and examining angiogenesis, follicle premature depletion and dynamics. Investigador.
2016 - 2018. The role of telomere maintenance in urologic maligancies.. Orientador.
2016 - 2017. Uncovering novel therapeutic targets that regulate the self-renewal capacity of colorectal cancer.. Orientador.
2015 - 2020. Targeting the telomere maintenance pathway for cancer diagnostics and therapeutics.. Investigador. Canadian Cancer Society.
2015 - 2020. Novel implications of THOR hypermethylation in telomere maintenance and gliomagenesis.. Investigador.
2015 - 2018. The diagnostic, prognostic and therapeutic role of THOR in breast cancer.. Orientador.
2015 - 2017. Utilization of THOR hypermethylation for stratification and noninvasive detection of cancer. Investigador.
2015 - 2016. McLaughlin Centre Accelerator Grants in Genomic Medicine and Health Informatics. Epigenetic Profiling in Severe Sepsis (EPSIS).. Investigador.
2015 - 2016. Epigenetic Profiling in Severe Sepsis (EPSIS).. Investigador.
2015 - 2016. miRNAs marcadores séricos de doença testicular ativa. Investigador.
2015 - 2016. Diagnostic, prognostic and therapeutic implications of THOR – Tert Hypermethylated Oncologic Region in breast cancer.. Investigador responsável.
2010 - 2015. Prediction and Prevention of glioma recurrence by targeting telomere dependent self-renewal capacity of tumor initiating cells.. Outra.
2012 - 2014. O papel da leptina no microambiente e oncogenese do carcinoma da prostata.. Investigador.
2010 - 2013. Exhaustion of tumor initiating cells by targeting their self-renewal capacity with telomerase inhibition. Outra.
2012 - 2012. hTERT methylation as a diagnostic and predictive tool for various tumors.. Outra.
2022/01/25 - 2023/01/25. “Epigenetic signatures of schizophrenia in an IPS derived model during neuronal differentiation”.
2021/07/01 - 2023/12/30. ALgarve Fit Ageing Score (ALFA Score): uma nova ferramenta integrada para melhorar a qualidade de vida e o envelhecimento saudável.. Investigador responsável. Comissão de Coordenação e Desenvolvimento Regional do Algarve.
2018 - 2021. Decoding breast cancer evolution through mutant allele differential expression signatures.
Produções
Pimenta, Jorge M.B.G.A.; Pires, Virgínia M.R.; Nolasco, Sofia; Castelo-Branco, Pedro; Marques, Carla C.; Apolónio, Joana; Azevedo, Rita; et al. 2022. "Post-transcriptional silencing of Bos taurus prion family genes and its impact on granulosa cell steroidogenesis". Biochemical and Biophysical Research Communications, 598: 95-99. https://doi.org/10.1016/j.bbrc.2022.02.012
Binnie, Alexandra; Fernandes, Emanuel; Almeida-Lousada, Helder; de Mello, Ramon Andrade; Castelo-Branco, Pedro. 2021. "CRISPR-based strategies in infectious disease diagnosis and therapy". Infection. https://doi.org/10.1007/s15010-020-01554-w
Pedro Castelo-Branco. 2021. "Identification of colorectal cancer associated biomarkers: an integrated analysis of miRNA expression". Aging, 13 (18): 21991-22029. https://doi.org/10.18632/aging.203556
Pedro Castelo-Branco. 2021. "Current and potential biomarkers in gastric cancer: a critical review of the literature". Future Oncology, 17 (25): 3383-3396. https://doi.org/10.2217/fon-2021-0084
Catarina Vizetto-Duarte; Pedro Castelo-Branco; Luísa Custódio. 2021. "Marine Natural Products as a Promising Source of Therapeutic Compounds to Target Cancer Stem Cells". Current Medicinal Chemistry, 28 (22): 4343-4355. https://doi.org/10.2174/0929867327666200320155053
Inês Faleiro; Vânia Palma Roberto; Secil Demirkol Canli; Nicolas A. Fraunhoffer; Juan Iovanna; Ali Osmay Gure; Wolfgang Link; Pedro Castelo-Branco. 2021. "DNA Methylation of PI3K/AKT Pathway-Related Genes Predicts Outcome in Patients with Pancreatic Cancer: A Comprehensive Bioinformatics-Based Study". Cancers. https://doi.org/10.3390/cancers13246354
Hélder Almeida-Lousada; André Mestre; Sara Ramalhete; Aryeh J. Price; Ramon Andrade de Mello; Ana D. Marreiros; Ricardo Pires das Neves; Pedro Castelo-Branco. 2021. "Screening for Colorectal Cancer Leading into a New Decade: The “Roaring ‘20s” for Epigenetic Biomarkers?". Current Oncology, 28 (6): 4874-4893. https://doi.org/10.3390/curroncol28060411
Ramon Andrade Bezerra De Mello; Rafael Voscaboinik; João Vittor Pires Luciano; Rafaela Vilela Cremonese; Giovanna Araujo Amaral; Pedro Castelo-Branco; Georgios Antoniou. 2021. "Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives". Cancers. https://doi.org/10.3390/cancers14010122
Lee, Donghyun D.; Komosa, Martin; Sudhaman, Sumedha; Leão, Ricardo; Zhang, Cindy H.; Apolonio, Joana D.; Hermanns, Thomas; et al. 2021. "Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer". Journal of Clinical Investigation, 131 (21). https://doi.org/10.1172/jci146915
Binnie, Alexandra; Walsh, Christopher J.; Hu, Pingzhao; Dwivedi, Dhruva J.; Fox-Robichaud, Alison; Liaw, Patricia C.; Tsang, Jennifer L. Y.; et al. 2020. "Epigenetic Profiling in Severe Sepsis". Critical Care Medicine, 48 (2): 142-150. https://doi.org/10.1097/ccm.0000000000004097
Binnie, Alexandra; Tsang, Jennifer L. Y.; Hu, Pingzhao; Carrasqueiro, Gabriela; Castelo-Branco, Pedro; dos Santos, Claudia C.. 2020. "Epigenetics of Sepsis". Critical Care Medicine. https://doi.org/10.1097/ccm.0000000000004247
De Mello, Ramon Andrade; Ayoub, Emili; Castelo-Branco, Pedro; De Almeida Zia, Victor Andre; Savio, Andre; Pozza, Daniel Humberto; Tadokoro, Hakaru; Teich, Nelson. 2020. "Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the U.K. Perspective.". Journal of Clinical Oncology, 38 (6_suppl): 689-689. https://doi.org/10.1200/jco.2020.38.6_suppl.689
Pedro Castelo-Branco. 2020. "New target therapies in advanced non-small cell lung cancer: a review of the literature and future perspectives". Journal of Clinical Medicine.
De Mello, Ramon Andrade; Neves, Nathália Moisés; Amaral, Giovanna Araújo; Lippo, Estela Gudin; Castelo-Branco, Pedro; Pozza, Daniel Humberto; Tajima, Carla Chizuru; Antoniou, Georgios. 2020. "The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer". Journal of Clinical Medicine, 9 (6). https://doi.org/10.3390/jcm9061918
Binnie, Alexandra; Tsang, Jennifer L. Y.; Hu, Pingzhao; Carrasqueiro, Gabriela; Castelo-Branco, Pedro; dos Santos, Claudia C.. 2020. "Epigenetics of Sepsis". Critical Care Medicine, 48 (5): 745-756. https://doi.org/10.1097/ccm.0000000000004247
Pedro Castelo-Branco. 2020. "A pilot study on DNA methylation profiles in critical Illness". Critical Care Medicine.
Pedro Castelo-Branco. 2020. "Histone modifications in diseases". Em Histone Modification in Therapy, 1-15. Vol. 20. Elsevier Translation Epigenetics Series.
Pedro Castelo-Branco. 2020. "Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the UK perspective". Journal of Clinical Oncology, 38: 689-689.
Adashek, Jacob J; Aguiar, Pedro N; Castelo-Branco, Pedro; Lopes, Gilberto L; De Mello, Ramon Andrade. 2019. "PALOMA-3 clinical trial: is there a significant benefit in overall survival for breast cancer? Is it worth it?". https://doi.org/10.2217/fon-2019-0044
Ramalhete, Sara Maria Ventura. 2019. "Epigenetic biomarkers as predictors of clinical outcomes in colorectal cancer". Mestrado. http://hdl.handle.net/10400.1/13422
Leão, Ricardo; Lee, Donghyun; Figueiredo, Arnaldo; Hermanns, Thomas; Wild, Peter; Komosa, Martin; Lau, Irene; et al. 2019. "Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer". https://doi.org/10.1002/ijc.31935
Almeida, Bernardo; Apolónio, Joana; Binnie, Alexandra; Castelo-Branco, Pedro. 2019. "Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers". http://hdl.handle.net/10400.1/12432
da Cunha, Bianca Rodrigues; Domingos, Célia; Stefanini, Ana Carolina Buzzo; Henrique, Tiago; Polachini, Giovana Mussi; Castelo-Branco, Pedro; Tajara, Eloiza Helena. 2019. "Cellular interactions in the tumor microenvironment: the role of secretome". https://doi.org/10.7150/jca.21780
De Mello, Ramon Andrade; Faleiro, Inês; Apolónio, Joana D; Tabori, Uri; Price, Aryeh J; Roberto, Vânia P; Castelo-Branco, Pedro. 2019. "Hot topics in epigenetic regulation of cancer self-renewal for pancreatic tumors: future trends". Future Oncology, 15 (7): 683-685. https://doi.org/10.2217/fon-2018-0153
Lee, Donghyun D.; Leão, Ricardo; Komosa, Martin; Gallo, Marco; Zhang, Cindy H.; Lipman, Tatiana; Remke, Marc; et al. 2019. "DNA hypermethylation within TERT promoter upregulates TERT expression in cancer". Journal of Clinical Investigation, 129 (1): 223-229. https://doi.org/10.1172/jci121303
da Cunha, Bianca Rodrigues; Domingos, Célia; Stefanini, Ana Carolina Buzzo; Henrique, Tiago; Polachini, Giovana Mussi; Castelo-Branco, Pedro; Tajara, Eloiza Helena. 2019. "Cellular Interactions in the Tumor Microenvironment: The Role of Secretome". Journal of Cancer, 10 (19): 4574-4587. https://doi.org/10.7150/jca.21780
Pedro Castelo-Branco. 2019. "Gastric Cancer". Em International Manual of Oncology Practice , 303-330.
Fonseca, André Filipe Afonso de Sousa. 2018. "Epigenetic of colorectal cancer: a focus on microRNAs". Mestrado. http://hdl.handle.net/10400.1/12546
Leão, Ricardo; Apolónio, Joana D.; Lee, Donghyun; Figueiredo, Arnaldo; Tabori, Uri; Castelo-Branco, Pedro. 2018. "Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer". https://doi.org/10.1186/s12929-018-0422-8
De Mello, Ramon Andrade; Aguiar, Pedro Nazareth; Tadokoro, Hakaru; Farias-Vieira, Tállita Meciany; Castelo-Branco, Pedro; de Lima Lopes, Gilberto; Pozza, Daniel Humberto. 2018. "MetaLanc9 as a novel biomarker for non-small cell lung cancer: promising treatments via a PGK1-activated AKT/mTOR pathway". Journal of Thoracic Disease, 10 (S16): S2076-S2078. https://doi.org/10.21037/jtd.2018.04.122
Leão, Ricardo; van Agthoven, Ton; Fadaak, Kamel; Castelo-Branco, Pedro; Jewett, Michael; Sweet, Joan; E. Ahmad, Ardalan; et al. 2018. "MP37-08 SERUM MIRNA PREDICTS VIABLE DISEASE POST-CHEMOTHERAPY IN TESTICULAR NON-SEMINOMA GERM CELL TUMOR PATIENTS". Journal of Urology, 199 (4S). https://doi.org/10.1016/j.juro.2018.02.1214
Gouvinhas, Cláudia; De Mello, Ramon Andrade; Oliveira, Daniela; Castro-Lopes, José Manuel; Castelo-Branco, Pedro; dos Santos, Ricardo Sales; Hespanhol, Venceslau; Pozza, Daniel Humberto. 2018. "Lung cancer: a brief review of epidemiology and screening". Future Oncology, 14 (6): 567-575. https://doi.org/10.2217/fon-2017-0486
De Mello, Ramon Andrade; Castelo-Branco, Luis; Castelo-Branco, Pedro; Pozza, Daniel Humberto; Vermeulen, Louis; Palacio, Sofia; Salzberg, Matthew; Lockhart, A. Craig. 2018. "What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?". American Society of Clinical Oncology Educational Book, (38): 249-261. https://doi.org/10.1200/edbk_198805
Pedro Castelo-Branco. 2018. "Method of diagnosing cancer comprising detection of the methylation signature in the hTERT promoter.". Estados Unidos.
Pedro Castelo-Branco. 2018. "What we will expect from novel therapies to Esophageal and Gastric malignancies ". Em American Society of Clinical Oncology Educational Book , 249-261.
De Mello, Ramon Andrade; Escriu, Carles; Castelo-Branco, Pedro; Cabral, Paloma Lucena; Mountzios, Giannis; Lopes, Gilberto de Lima; Madureira, Pedro. 2017. "Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis". Oncotarget, 9 (14). https://doi.org/10.18632/oncotarget.23668
Faleiro, Inês; Apolónio, Joana Dias; Price, Aryeh J; De Mello, Ramon Andrade; Roberto, Vânia Palma; Tabori, Uri; Castelo-Branco, Pedro. 2017. "The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer". Future Oncology, 13 (23): 2045-2051. https://doi.org/10.2217/fon-2017-0167
Leão, Ricardo; Domingos, Célia; Figueiredo, Arnaldo; Hamilton, Robert; Tabori, Uri; Castelo-Branco, Pedro. 2017. "Cancer Stem Cells in Prostate Cancer: Implications for Targeted Therapy". Urologia Internationalis, 99 (2): 125-136. https://doi.org/10.1159/000455160
Castelo-Branco, Pedro; Leao, Ricardo; Lipman, Tatiana; Campbell, Brittany; Lee, Donghyun; Price, Aryeh; Zhang, Cindy; et al. 2016. "A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: A retrospective cohort study". https://doi.org/10.18632/oncotarget.10639
Faleiro, Inês; Leão, Ricardo; Binnie, Alexandra; Andrade de Mello, Ramon; Maia, Ana Teresa; Castelo-Branco, Pedro. 2016. "Epigenetic therapy in urologic cancers: an update on clinical trials". https://doi.org/10.18632/oncotarget.14226
Aguiar, Pedro Nazareth Jr.; Muniz, Thiago Pimentel; Miranda, Raelson Rodrigues; Tadokoro, Hakaru; Forones, Nora Manoukian; Monteiro, Inês-de-Paula; Castelo-Branco, Pedro; Janjigian, Yelena Y.; Mello, Ramon Andrade de. 2016. "Current advances in targeted therapies for metastatic gastric cancer: improving patient care". https://doi.org/10.2217/fon.15.348
Aguiar, Pedro N; Santoro, Ilka Lopes; Tadokoro, Hakaru; de Lima Lopes, Gilberto; Filardi, Bruno Andraus; Oliveira, Pedro; Castelo-Branco, Pedro; Mountzios, Giannis; de Mello, Ramon Andrade. 2016. "A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker". Immunotherapy, 8 (9): 1011-1019. https://doi.org/10.2217/imt-2016-0032
Castelo-Branco, Pedro; Leão, Ricardo; Lipman, Tatiana; Campbell, Brittany; Lee, Donghyun; Price, Aryeh; Zhang, Cindy; et al. 2016. "A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study". Oncotarget, 7 (36). https://doi.org/10.18632/oncotarget.10639
Ernst, Aurélie; Jones, David T.W.; Maass, Kendra K.; Rode, Agata; Deeg, Katharina I.; Jebaraj, Billy Michael Chelliah; Korshunov, Andrey; et al. 2016. "Telomere dysfunction and chromothripsis". International Journal of Cancer, 138 (12): 2905-2914. https://doi.org/10.1002/ijc.30033
Aguiar, Pedro Nazareth; Muniz, Thiago Pimentel; Miranda, Raelson Rodrigues; Tadokoro, Hakaru; Forones, Nora Manoukian; Monteiro, Ines-de-Paula; Castelo-Branco, Pedro; Janjigian, Yelena Y; de Mello, Ramon Andrade. 2016. "Current advances in targeted therapies for metastatic gastric cancer: improving patient care". Future Oncology, 12 (6): 839-854. https://doi.org/10.2217/fon.15.348
Mistry, Matthew; Zhukova, Nataliya; Merico, Daniele; Rakopoulos, Patricia; Krishnatry, Rahul; Shago, Mary; Stavropoulos, James; et al. 2015. "BRAF Mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma". https://doi.org/10.1200/JCO.2014.58.3922
Zhukova, Nataliya; Ramaswamy, Vijay; Remke, Marc; Martin, Dianna C.; Castelo-Branco, Pedro; Zhang, Cindy H.; Fraser, Michael; et al. 2014. "WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma". https://doi.org/10.1186/s40478-014-0174-y
Barszczyk, Mark; Buczkowicz, Pawel; Castelo-Branco, Pedro; Mack, Stephen C.; Ramaswamy, Vijay; Mangerel, Joshua; Agnihotri, Sameer; et al. 2014. "Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells". https://doi.org/10.1007/s00401-014-1327-6
Mangerel, Joshua; Price, Aryeh; Castelo-Branco, Pedro; Brzezinski, Jack; Buczkowicz, Pawel; Rakopoulos, Patricia; Merino, Diana; et al. 2014. "Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors". Acta Neuropathologica, 128 (6): 853-862. https://doi.org/10.1007/s00401-014-1348-1
Taylor, M. D.; Mack, S.; Witt, H.; Dirks, P.; Pfister, S.; Korshunov, A.; Pedro Castelo-Branco. 2014. "EPIGENOME ALTERATIONS DEFINE LETHAL CIMP POSITIVE EPENDYMOMAS OF INFANCY". Nature. https://doi.org/10.1093/neuonc/nou206.58
Pedro Castelo-Branco. 2014. "Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.". Acta Neuropathol..
Pedro Castelo-Branco. 2014. "Comprehensive genomic analysis of diffuse intrinsic pontine gliomas unravels three molecular subgroups and a novel cancer driver.". Nature Genetics, . https://doi.org/10.1038/ng.2936.
Pedro Castelo-Branco. 2014. "Epigenomic alterations define lethal CIMP-positive ependymomas of infancy.". Nature.
Pagliaro, Sarah Beatriz de Oliveira. 2013. "Cancro da próstata : efeitos da quimioterapia in vitro em células estaminais cancerígenas". Mestrado. http://hdl.handle.net/10316/35775
Castelo-Branco, Pedro; Choufani, Sanaa; Mack, Stephen; Gallagher, Denis; Zhang, Cindy; Lipman, Tatiana; Zhukova, Nataliya; et al. 2013. "Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study". The Lancet Oncology, 14 (6): 534-542. https://doi.org/10.1016/s1470-2045(13)70110-4
Pedro Castelo-Branco. 2013. "Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.". Journal of Clinical Oncology.. https://doi.org/10.1200/JCO.2012.48.5052
Pedro Castelo-Branco. 2013. "Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.". The Lancet Oncology. https://doi.org/10.1016/S1470-2045(13)70110-4
Castelo-Branco, Pedro; Tabori, Uri. 2012. "Promises and challenges of exhausting pediatric neural cancer stem cells". Pediatric Research, 71 (2-4): 523-528. https://doi.org/10.1038/pr.2011.63
Pedro Castelo-Branco. 2012. "Monoallelic Expression Determines Oncogenic Progression and Outcome in Benign and Malignant Brain Tumors". Journal of Cancer Research and Oncobiology.
Pedro Castelo-Branco. 2012. "Monoallelic expression determines oncogenic progression and outcome in benign and malignant brain tumors.". Cancer Research. https://doi.org/10.1158/0008-5472.CAN-11-2266
Pedro Castelo-Branco. 2012. "Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.". Nature. https://doi.org/10.1038/nature10833
Castelo-Branco, P.; Zhang, C.; Lipman, T.; Fujitani, M.; Hansford, L.; Clarke, I.; Harley, C. B.; et al. 2011. "Neural Tumor-Initiating Cells Have Distinct Telomere Maintenance and Can be Safely Targeted for Telomerase Inhibition". Clinical Cancer Research, 17 (1): 111-121. https://doi.org/10.1158/1078-0432.ccr-10-2075
Pedro Castelo-Branco. 2011. "Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition.". Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-10-2075
Castelo-Branco, P; Passer, B J; Buhrman, J S; Antoszczyk, S; Marinelli, M; Zaupa, C; Rabkin, S D; Martuza, R L. 2010. "Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer". Gene Therapy, 17 (6): 805-810. https://doi.org/10.1038/gt.2010.20
Pedro Castelo-Branco. 2010. "Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.". Gene Therapy. http://www.ncbi.nlm.nih.gov/pubmed/20220784
Passer, B J; Castelo-Branco, P; Buhrman, J S; Varghese, S; Rabkin, S D; Martuza, R L. 2009. "Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells". Cancer Gene Therapy, 16 (7): 551-560. https://doi.org/10.1038/cgt.2009.10
Pedro Castelo-Branco. 2009. "Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells.". Cancer Gene Therapy.
Liu, Ta-Chiang; Castelo-Branco, Pedro; Rabkin, Samuel D; Martuza, Robert L. 2008. "Trichostatin A and Oncolytic HSV Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects". Molecular Therapy, 16 (6): 1041-1047. https://doi.org/10.1038/mt.2008.58
Binnie, A.. 2006. "Homologous gene sequences mediate transcription-domain formation". Journal of Cell Science, 119 (18): 3876-3887. https://doi.org/10.1242/jcs.03050
Castelo-Branco, P.; Furger, A.; Wollerton, M.; Smith, C.; Moreira, A.; Proudfoot, N.. 2004. "Polypyrimidine Tract Binding Protein Modulates Efficiency of Polyadenylation". Molecular and Cellular Biology, 24 (10): 4174-4183. https://doi.org/10.1128/mcb.24.10.4174-4183.2004
Pedro Castelo-Branco. 2004. "Polypyrimidine tract binding protein modulates efficiency of polyadenylation". Mol. Cell. Biol.. https://doi.org/10.1128/MCB.24.10.4174-4183.2004
